Markets:

Overview

News

Currencies

International

Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

7.681 +0.781 (+11.32%)

Streaming Delayed Price Updated: 3:15 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

February 08, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗

January 31, 2022

Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...

Via Benzinga

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

January 25, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses ↗

January 24, 2022

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying...

Via Benzinga

Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants

January 24, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 21, 2022

From Arcturus Therapeutics

Via Business Wire

65 Biggest Movers From Yesterday ↗

January 19, 2022

Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 18, 2022

Gainers Brickell Biotech (NASDAQ:BBI) shares moved upwards by 71.1% to $0.36 during Tuesday's regular session. Brickell Biotech's stock is trading at a volume of...

Via Benzinga

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 17, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs ↗

December 16, 2021

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

December 16, 2021

Gainers Calliditas Therapeutics (NASDAQ:CALT...

Via Benzinga

58 Biggest Movers From Yesterday ↗

December 17, 2021

Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price...

Via Benzinga

31 Stocks Moving In Thursday's Mid-Day Session ↗

December 16, 2021

Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce...

Via Benzinga

Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials

December 16, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors

December 13, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

November 22, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 18, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress

November 08, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

October 25, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

92 Biggest Movers From Friday ↗

November 08, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...

Via Benzinga

Arcturus Therapeutics Announces Leadership Appointments

October 21, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 20, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

October 12, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT ↗

October 06, 2021

Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal...

Via Benzinga

Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83 ↗

September 29, 2021

Arcturus Therapeutics sees its Relative Strength Rating hit the 80-plus level.

Via Investor's Business Daily

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

September 22, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Vietnam's Health Ministry Approves Phase 2, Phase 3 Cohorts Of Arcturus' COVID-19 Vaccine Trial ↗

September 22, 2021

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has completed dosing of 100 subjects for the Phase 1 portion of the ARCT-154 Phase 1/2/3 trial, which consisted...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗

September 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...

Via Benzinga

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

September 22, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Earnings Perspective: Return On Capital Employed ↗

September 15, 2021

According to Benzinga Pro data, during Q2, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $2.00 million. Earnings were up 6.84%, but Arcturus Therapeutics still reported an...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.